Apollo Therapeutics, a unique collaboration between UCL, Imperial College London and the University of Cambridge, and three global pharmaceutical companies, has attracted a further £226.5m of further investment to translate scientific advances for patient benefit. This latest Series C financing significantly adds to the $195m previously raised by the Company. The financing round, led by Patient Square Capital, saw the inclusion of new investors such as M&G plc and two of the largest US public pension plans, along with existing investor Rock Springs Capital.

https://www.miragenews.com/apollo-therapeutics-nets-226-5m-for-ucl-medical-1078979/

#miragenews